Overview

  • Product name
    CPT 11 (Irinotecan), DNA topoisomerase I inhibitor
  • Description
    Potent DNA topoisomerase I inhibitor
  • Alternative names
    • Irinotecan Hydrochloride
  • Biological description
    Potent DNA topoisomerase I inhibitor. Displays antitumor activity against a variety of tumor types. Active metabolite SN38 (ab141108) also available.
  • Purity
    > 99%

Properties

Applications

Our Abpromise guarantee covers the use of ab141107 in the following tested applications.

The application notes include recommended starting dilutions; optimal dilutions/concentrations should be determined by the end user.

Application Abreviews Notes
Functional Studies Use at an assay dependent concentration.

Images

  • ab2893 staining γH2A.X in HeLa cells treated with CPT 11 (Irinotecan) (ab141107), by ICC/IF. Increase of γH2A.X nuclear expression correlates with increased concentration of CPT 11 (Irinotecan), as described in literature.
    The cells were incubated at 37°C for 6 hours in media containing different concentrations of ab141107 (CPT 11 (Irinotecan)) in DMSO, fixed with 100% methanol for 5 minutes at -20°C and blocked with PBS containing 10% goat serum, 0.3 M glycine, 1% BSA and 0.1% tween for 2h at room temperature. Staining of the treated cells with ab2893 (5 µg/ml) was performed overnight at 4°C in PBS containing 1% BSA and 0.1% tween. A DyLight 488 anti-rabbit polyclonal antibody (ab96899) at 1/250 dilution was used as the secondary antibody. Nuclei were counterstained with DAPI and are shown in blue.

References

This product has been referenced in:
  • Albertsson P  et al. Low-dosage metronomic chemotherapy and angiogenesis: topoisomerase inhibitors irinotecan and mitoxantrone stimulate VEGF-A-mediated angiogenesis. APMIS 120:147-56 (2012). Read more (PubMed: 22229270) »
  • Morton CL  et al. Activation and antitumor activity of CPT-11 in plasma esterase-deficient mice. Cancer Chemother Pharmacol 56:629-36 (2005). Read more (PubMed: 15918039) »
  • Vassal G  et al. Therapeutic activity of CPT-11, a DNA-topoisomerase I inhibitor, against peripheral primitive neuroectodermal tumour and neuroblastoma xenografts. Br J Cancer 74:537-45 (1996). Read more (PubMed: 8761367) »

Customer reviews and Q&As

There are currently no Customer reviews or Questions for ab141107.
Please use the links above to contact us or submit feedback about this product.

Please note: All products are "FOR RESEARCH USE ONLY AND ARE NOT INTENDED FOR DIAGNOSTIC OR THERAPEUTIC USE, NOT FOR USE IN HUMANS"

Sign up